212 related articles for article (PubMed ID: 12612508)
41. Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus.
Hur C; Nishioka NS; Gazelle GS
J Natl Cancer Inst; 2004 Feb; 96(4):316-25. PubMed ID: 14970280
[TBL] [Abstract][Full Text] [Related]
42. The cost of surveillance for adenocarcinoma complicating Barrett's esophagus.
Achkar E; Carey W
Am J Gastroenterol; 1988 Mar; 83(3):291-4. PubMed ID: 3125739
[TBL] [Abstract][Full Text] [Related]
43. The rationale for screening and surveillance of Barrett's metaplasia.
Wani S; Sharma P
Best Pract Res Clin Gastroenterol; 2006; 20(5):829-42. PubMed ID: 16997164
[TBL] [Abstract][Full Text] [Related]
44. Cost-Effectiveness of Screening, Surveillance, and Endoscopic Eradication Therapies for Managing the Burden of Esophageal Adenocarcinoma.
Rubenstein JH; Inadomi JM
Gastrointest Endosc Clin N Am; 2021 Jan; 31(1):77-90. PubMed ID: 33213801
[TBL] [Abstract][Full Text] [Related]
45. The association between alcohol and reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
Anderson LA; Cantwell MM; Watson RG; Johnston BT; Murphy SJ; Ferguson HR; McGuigan J; Comber H; Reynolds JV; Murray LJ
Gastroenterology; 2009 Mar; 136(3):799-805. PubMed ID: 19162028
[TBL] [Abstract][Full Text] [Related]
46. Effectiveness and Cost-Effectiveness of Endoscopic Screening and Surveillance.
Saxena N; Inadomi JM
Gastrointest Endosc Clin N Am; 2017 Jul; 27(3):397-421. PubMed ID: 28577764
[TBL] [Abstract][Full Text] [Related]
47. Cost-effectiveness model of endoscopic biopsy for eosinophilic esophagitis in patients with refractory GERD.
Miller SM; Goldstein JL; Gerson LB
Am J Gastroenterol; 2011 Aug; 106(8):1439-45. PubMed ID: 21448144
[TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus.
Sharaiha RZ; Freedberg DE; Abrams JA; Wang YC
Dig Dis Sci; 2014 Jun; 59(6):1222-30. PubMed ID: 24795040
[TBL] [Abstract][Full Text] [Related]
49. How far to go? Screening and surveillance in Barrett's esophagus.
Lieberman DA; Sampliner RE
Am J Manag Care; 2001 Feb; 7(1 Suppl):S19-26. PubMed ID: 11225349
[TBL] [Abstract][Full Text] [Related]
50. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years.
Drewitz DJ; Sampliner RE; Garewal HS
Am J Gastroenterol; 1997 Feb; 92(2):212-5. PubMed ID: 9040193
[TBL] [Abstract][Full Text] [Related]
51. [Barrett-Screening: Rational, current concepts and perspectives].
Weismüller J; Thieme R; Hoffmeister A; Weismüller T; Gockel I
Z Gastroenterol; 2019 Mar; 57(3):317-326. PubMed ID: 30861556
[TBL] [Abstract][Full Text] [Related]
52. Screening and surveillance of Barrett's esophagus.
Regula J
Dig Dis; 2009; 27(1):54-7. PubMed ID: 19439961
[TBL] [Abstract][Full Text] [Related]
53. Endoscopic versus surgical therapy for early cancer in Barrett's esophagus: a decision analysis.
Pohl H; Sonnenberg A; Strobel S; Eckardt A; Rösch T
Gastrointest Endosc; 2009 Oct; 70(4):623-31. PubMed ID: 19394011
[TBL] [Abstract][Full Text] [Related]
54. [Recommended endoscopic surveillance of patients with Barrett's esophagus (BE) is a cost-effective strategy?].
Remes-Troche JM; Ramírez-Arias JF; Gómez-Escudero O; Valdovinos-Andraca F; Vargas-Vorácková F
Rev Gastroenterol Mex; 2006; 71(1):46-54. PubMed ID: 17061478
[TBL] [Abstract][Full Text] [Related]
55. A cost analysis of outpatient care for patients with Barrett's esophagus in a managed care setting.
Eloubeidi MA; Homan RK; Martz MD; Theobald KE; Provenzale D
Am J Gastroenterol; 1999 Aug; 94(8):2033-6. PubMed ID: 10445524
[TBL] [Abstract][Full Text] [Related]
56. Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus.
Vij R; Triadafilopoulos G; Owens DK; Kunz P; Sanders GD
Gastrointest Endosc; 2004 Nov; 60(5):739-56. PubMed ID: 15557950
[TBL] [Abstract][Full Text] [Related]
57. Incidence of adenocarcinoma among patients with Barrett's esophagus.
Hvid-Jensen F; Pedersen L; Drewes AM; Sørensen HT; Funch-Jensen P
N Engl J Med; 2011 Oct; 365(15):1375-83. PubMed ID: 21995385
[TBL] [Abstract][Full Text] [Related]
58. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study.
Bytzer P; Christensen PB; Damkier P; Vinding K; Seersholm N
Am J Gastroenterol; 1999 Jan; 94(1):86-91. PubMed ID: 9934736
[TBL] [Abstract][Full Text] [Related]
59. Medical treatment of Barrett's esophagus: can it prevent cancer?
Sampliner RE
Surg Oncol Clin N Am; 2009 Jul; 18(3):503-8. PubMed ID: 19500739
[TBL] [Abstract][Full Text] [Related]
60. The value of medical imaging in uncomplicated and complicated Barrett's esophagus.
De Backer AI; De Schepper AM; Pelckmans P
Acta Gastroenterol Belg; 2000; 63(1):22-8. PubMed ID: 10907315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
